Electronegative low‐density lipoprotein of patients with metabolic syndrome induces pathogenesis of aorta through disruption of the stimulated by retinoic acid 6 cascade

Autor: An-Sheng Lee, Chao-Hung Chen, Kun-Der Lin, Hua-Chen Chan, Chih-Sheng Chu, Pi-Jung Hsiao, Mei-Yueh Lee, Shyi-Jang Shin, Liang-Yin Ke, Chu-Huang Chen
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
Basic Science and Research
medicine.medical_specialty
Endocrinology
Diabetes and Metabolism
p38 mitogen-activated protein kinases
Aortic Diseases
Retinoic acid
Electronegative low‐density lipoprotein
Diseases of the endocrine glands. Clinical endocrinology
Pathogenesis
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
medicine.artery
Internal medicine
Internal Medicine
medicine
Animals
Humans
Receptor
Cells
Cultured
Aorta
Metabolic Syndrome
business.industry
Kinase
Membrane Proteins
Articles
General Medicine
Transfection
Middle Aged
RC648-665
Lipoproteins
LDL
Mice
Inbred C57BL
030104 developmental biology
Endocrinology
chemistry
030220 oncology & carcinogenesis
Original Article
Female
Stimulated by retinoic acid 6
business
Signal Transduction
Lipoprotein
Zdroj: Journal of Diabetes Investigation, Vol 11, Iss 3, Pp 535-544 (2020)
Journal of Diabetes Investigation
ISSN: 2040-1116
2040-1124
Popis: Aims/Introduction Electronegative low‐density lipoprotein (L5) is the most atherogenic fraction of low‐density lipoprotein and is elevated in people with metabolic syndrome (MetS), whereas the retinol‐binding protein 4 receptor (stimulated by retinoic acid 6 [STRA6]) cascade is disrupted in various organs of patients with obesity‐related diseases. Our objective was to investigate whether L5 from MetS patients capably induces pathogenesis of aorta through disrupting the STRA6 cascade. Material and Methods We examined the in vivo and in vitro effects of L5 on the STRA6 cascade and aortic atherogenic markers. To investigate the role of this cascade on atherosclerotic formation, crbp1 transfection was carried out in vitro. Results This study shows that L5 activates atherogenic markers (p38 mitogen‐activated protein kinases, pSmad2 and matrix metallopeptidase 9) and simultaneously suppresses STRA6 signals (STRA6, cellular retinol‐binding protein 1, lecithin‐retinol acyltransferase, retinoic acid receptor‐α and retinoid X receptor‐α) in aortas of L5‐injected mice and L5‐treated human aortic endothelial cell lines and human aortic smooth muscle cell lines. These L5‐induced changes of the STRA6 cascade and atherogenic markers were reversed in aortas of LOX1−/− mice and in LOX1 ribonucleic acid‐silenced human aortic endothelial cell lines and human aortic smooth muscle cell lines. Furthermore, crbp1 gene transfection reversed the disruption of the STRA6 cascade, the phosphorylation of p38 mitogen‐activated protein kinases and Smad2, and the elevation of matrix metallopeptidase 9 in L5‐treated human aortic endothelial cell lines. Conclusions This study shows that L5 from MetS patients induces atherogenic markers by disrupting STRA6 signaling. Suppression of STRA6 might be one novel pathogenesis of aorta in patients with MetS.
Dyslipoproteinemia can cause aortic injuries by utilizing electronegative low‐density lipoprotein caused disruption of stimulated by retinoic acid 6 signaling. The suppression of stimulated by retinoic acid 6 might be one novel pathogenesis of aorta in people with metabolic syndrome.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje